[
  {
    "ts": "2025-06-15T09:38:50+00:00",
    "headline": "Biogen, UCB Present Positive Phase 3 Results for Lupus Drug Candidate at EULAR 2025",
    "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the 11 most profitable NASDAQ stocks to buy now. On June 12, UCB and Biogen presented additional detailed results from the Phase 3 PHOENYCS GO study, evaluating dapirolizumab pegol (DZP), which is a novel Fc-free anti-CD40L drug candidate. These results were unveiled at EULAR 2025, the European Alliance of […]",
    "url": "https://finance.yahoo.com/news/biogen-ucb-present-positive-phase-093850004.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "71f7b0e1-bb2b-3205-a3c3-12913e4ffe20",
      "content": {
        "id": "71f7b0e1-bb2b-3205-a3c3-12913e4ffe20",
        "contentType": "STORY",
        "title": "Biogen, UCB Present Positive Phase 3 Results for Lupus Drug Candidate at EULAR 2025",
        "description": "",
        "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the 11 most profitable NASDAQ stocks to buy now. On June 12, UCB and Biogen presented additional detailed results from the Phase 3 PHOENYCS GO study, evaluating dapirolizumab pegol (DZP), which is a novel Fc-free anti-CD40L drug candidate. These results were unveiled at EULAR 2025, the European Alliance of […]",
        "pubDate": "2025-06-15T09:38:50Z",
        "displayTime": "2025-06-15T09:38:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Biogen, UCB Present Positive Phase 3 Results for Lupus Drug Candidate at EULAR 2025",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6ixRM3d_RV3w5hCozODMpg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HIrwEXIPFTzVGiKAPI9LJA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-ucb-present-positive-phase-093850004.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-ucb-present-positive-phase-093850004.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]